Herpes Zoster Treatment

Herpes Zoster Treatment

Global Herpes Zoster Treatment Market to Reach US$266.4 Million by 2030

The global market for Herpes Zoster Treatment estimated at US$232.8 Million in the year 2023, is expected to reach US$266.4 Million by 2030, growing at a CAGR of 1.9% over the analysis period 2023-2030. Antiviral Medications, one of the segments analyzed in the report, is expected to record a 2.5% CAGR and reach US$134.0 Million by the end of the analysis period. Growth in the Anti-Inflammatory Medications segment is estimated at 1.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$63.4 Million While China is Forecast to Grow at 4.2% CAGR

The Herpes Zoster Treatment market in the U.S. is estimated at US$63.4 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$52.0 Million by the year 2030 trailing a CAGR of 4.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.4% and 1.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 0.9% CAGR.

Global Herpes Zoster Treatment Market - Key Trends and Drivers Summarized

Herpes zoster, commonly known as shingles, is a viral infection that results from the reactivation of the varicella-zoster virus (VZV), the same virus that causes chickenpox. After a person recovers from chickenpox, the virus remains dormant in the nerve tissue and can reactivate years later, causing herpes zoster. The disease is characterized by a painful rash that may appear as a stripe of blisters on one side of the body, typically the torso or face. Treatment for herpes zoster aims to reduce the severity and duration of pain, shorten the duration of the rash, and prevent complications such as postherpetic neuralgia (PHN), a condition where severe pain persists long after the rash has cleared. Common treatment options include antiviral drugs such as acyclovir, valacyclovir, and famciclovir, which are most effective when started within 72 hours of the onset of the rash. In addition to antivirals, pain management strategies may include corticosteroids, analgesics, and topical agents to alleviate the symptoms of the rash and neuralgia.

Recent advances in the understanding of herpes zoster have led to improved prevention and treatment strategies. One of the significant developments is the introduction of highly effective vaccines that reduce the risk of developing herpes zoster and its complications. These vaccines are particularly recommended for older adults, as the risk and severity of the disease increase significantly with age. The newer recombinant zoster vaccine (RZV, Shingrix) has shown high efficacy in preventing both herpes zoster and postherpetic neuralgia, even among the elderly population. Additionally, ongoing research continues to explore the underlying mechanisms of VZV reactivation and the potential for novel antiviral agents that can more effectively target the virus. Understanding the relationship between the immune system and VZV latency is critical for developing therapies that could prevent the virus from reactivating rather than merely managing its symptoms.

The growth in the herpes zoster treatment market is driven by several factors, including an aging global population, increased awareness of the disease and its potential complications, and advancements in vaccine technology. As the population ages, the number of individuals at risk of VZV reactivation increases, creating a significant demand for effective treatment and prevention options. Public health campaigns and healthcare provider education efforts have raised awareness about the importance of vaccination against herpes zoster, particularly among populations over 50 years of age, which has contributed to increased vaccine uptake. Additionally, improvements in vaccine formulations and the introduction of new antiviral treatments are expected to enhance patient outcomes and drive market growth. Furthermore, changing healthcare policies and insurance coverage of vaccinations play a crucial role in the accessibility and affordability of both preventative and therapeutic options, supporting wider adoption and driving growth in the sector. These trends highlight the dynamic nature of the herpes zoster treatment market and underscore the continuing need for innovative solutions in managing this painful and potentially debilitating condition.

Select Competitors (Total 86 Featured) -

• Anida Pharma Inc.
• Beijing Luzhu Biotechnology Co., Ltd.
• CHA Vaccine Institute
• Curevo
• Dynavax Technologies Corporation
• GSK Plc
• HilleVax
• Innorna Co., Ltd.
• Jiangsu Rec-Biotechnology Co., Ltd.
• Moderna, Inc.
• Pfizer, Inc.
• Saol Therapeutics
• SK bioscience
• VBI Vaccines, Inc.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.